David Polsky, MD, PhD

Articles

Dr. Polsky on the Association Between ctDNA and Survival in Melanoma

June 11th 2020

David Polsky, MD, PhD, on the association between circulating tumor DNA and survival in melanoma.

Dr. Polsky on the Clinical Validity of ctDNA in BRAF-Mutant Melanoma

March 23rd 2020

David Polsky, MD, PhD, discusses the use of circulating tumor DNA (ctDNA) in the COMBI-d trial on melanoma.

Dr. Polsky on the Unmet Need of Clinical Utility in Liquid Biopsy

March 10th 2020

David Polsky, MD, PhD, discusses the unmet need of clinical utility in liquid biopsy.

Dr. Polsky on the Exploration of Blood-Based Biomarkers in Melanoma

January 30th 2020

David Polsky, MD, PhD, discusses the exploration of blood-based biomarkers in melanoma.

Dr. Polsky on Potential Applications of ctDNA in Melanoma

November 9th 2019

David Polsky, MD, PhD, discusses potential applications of circulating tumor DNA as a biomarker in melanoma.

Dr. Polsky on Validating ctDNA as a Biomarker in BRAF-Mutant Melanoma

September 10th 2019

David Polsky, MD, PhD, Alfred W. Kopf, MD Professor of Dermatologic Oncology, Ronald O. Perelman Department of Dermatology, professor, Department of Pathology, and director, Pigmented Lesion Service, NYU Langone’s Perlmutter Cancer Center, discusses the next steps that have to be taken to validate the clinical utility of circulating tumor DNA (ctDNA) as a biomarker in BRAF-mutant melanoma.

Dr. Polsky on the Predictive Value of ctDNA in BRAF-Mutant Melanoma

July 30th 2019

David Polsky, MD, PhD, Alfred W. Kopf, MD Professor of Dermatologic Oncology, Ronald O. Perelman Department of Dermatology, professor, Department of Pathology, and director, Pigmented Lesion Service, NYU Langone’s Perlmutter Cancer Center, discusses the predictive value of circulating tumor DNA (ctDNA) in BRAF-mutant melanoma.

Dr. Polsky on Using ctDNA as a Biomarker for Melanoma

July 2nd 2019

David Polsky, MD, PhD, discusses using circulating tumor DNA kinetics as a biomarker to predict survival and monitor disease activity in patients with unresectable or metastatic melanoma.

x